• Viridian Therapeutics plans to initiate a registrational trial of subcutaneous VRDN-008 in myasthenia gravis in mid-2027.
• Phase 1 healthy-volunteer data showed a peak IgG reduction of 74%, with sustained reductions through eight weeks following dosing.
• VRDN-008 demonstrated a half-life of 15-18 days, supporting potential dosing every eight weeks.
• Treatment was generally well tolerated, with no serious adverse events or dose-limiting toxicities.
• The planned trial will compare dosing every eight weeks, dosing every four weeks and placebo, using MG-ADL as the primary endpoint.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Viridian Therapeutics Inc. published the original content used to generate this news brief on November 09, 2026, and is solely responsible for the information contained therein.